What the STEP trials actually showed The STEP trial program was a series of large, randomized, double-blind, placebo-controlled studies that established semaglutide 2.4mg as a weight management intervention
Novo Nordisk assigns a two-year ( 24-month) expiration date to Ozempic and Wegovy
The 24-week mark represented the midpoint, with average losses reaching 17% and significant improvements in waist measurements, blood pressure, and metabolic markers
Semaglutide works dramatically better for weight loss but comes with a real cost in terms of tolerability, especially in the early weeks
Genetics may also contribute to the appearance of cellulite
According to a 2025 study, A sizeable proportion of exercisers and recreational athletes contemplated GLP-1 agonist use for body image enhancement purposes. The real question is, how does semaglutide affect athletic performance